Search results
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo News· 11 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Motley Fool via Yahoo Finance· 3 weeks agoJohnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer...
J&J profit edges past Street view after deals delay Stelara competition
Reuters via Yahoo Finance· 3 months agoJohnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped...
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Reuters via Yahoo News· 11 months ago(Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of...
Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar
Zacks via Yahoo Finance· 8 months agoNovartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the...
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
Reuters via Yahoo News· 1 year ago(Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for...
Unexpected drugs make first round of Medicare negotiations
The Hill via Yahoo News· 8 months agoThe Centers for Medicare and Medicaid Services (CMS) have officially named the first 10 drugs chosen...
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Motley Fool· 2 years agoIf a company is able to secure approval for a drug treatment and swipe market share from other...
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Motley Fool· 6 months agoJohnson & Johnson (NYSE: JNJ) is no longer the same company that investors have known for decades....
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
Zacks via Yahoo Finance· 8 months agoAbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week...